Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 3, 2010, Pages 307-313

  Cartwright, Thomas ^a,b   McCollum, David ^a,c   Boehm, Kristi A ^a  

^a US Oncology   (United States)

^b Ocala Oncology   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Capecitabine; Chemotherapy; Colorectal cancer; Irinotecan

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

ADVANCED CANCER; ANEMIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; ILEUS; LUNG EMBOLISM; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LEUCOVORIN; MULTICENTER STUDIES AS TOPIC; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77953358294     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d27361     Document Type: Review

References (53)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society. Available at: http://www.cancer.org/docroot/stt/ stt-0.asp?from-fast. Accessed July 28, 2009.
2. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008;19:447-464.
3. Xeloda prescribing information. Nutley, NJ: Roche Laboratories Inc. Available at: http://www.rocheusa.com/products/xeloda/ppi.pdf. Accessed July 28, 2009.
4. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23-44.
5. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
6. Rea DW, Nortier JW, Ten Bokkel Huinink WW, et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol. 2005;16:1123-1132.
7. Delord JP, Pierga JY, Dieras V, et al. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer. 2005;92: 820-826.
8. Bajetta E, Di Bartolomeo M, Mariani L, et al; Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer. 2004;100:279-287.
9. Cartwright T, Lopez T, Vukelja SJ, et al. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5:50-56.
10. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
11. Van Cutsem E, Twelves C, Cassidy J, et al; Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
12. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006-2012.
13. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008;19:1720-1726.
14. Ducreux M, Bennouna J, Hebbar M, et al. Douillard efficacy and safety findings from a randomized phase III study of capecitabine (X)- oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV- O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol. 2007;25(18S):170s. Abstract 4029.
15. Díaz-Rubio E, Tabernero J, Gómez-España A, et al; Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007;25:4224-4230.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Muñoz A, Salud A, Alonso V, et al. Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC). J Clin Oncol. 2004;22. Abstract 3610.
18. Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008;19:920-926.
19. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779-4786.
20. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized controlled trial. Lancet. 2007;370:135-142.
21. Reinacher-Schick AC, Kubicka S, Freier W, et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/ oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO colorectal study group (AIO trial 0604). J Clin Oncol. 2008;26(15S):185s. Abstract 4030.
22. Garcia Alfonso P, Méndez M, Muñoz A, et al. A phase II trial of capecitabine and irinotecan in a biweekly schedule in patients with previously untreated advanced colorectal cancer (ACRC). In: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 481.
23. Garcia Alfonso P, Muñoz-Martín A, Martínez- Martín V, et al. First-line treatment with a combination of bevacizumab and biweekly XELIRI in metastatic colorectal cancer (mCRC). In: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 482.
24. Bollina R, Beretta G, Toniolo D, et al. Capecitabine (C) and irinotecan (i) (CAPIRI): a good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first line chemotherapy (CT). Preliminary results of a phase II trial. Proc Am Soc Clin Oncol. 2003;22. Abstract 1332.
25. Willer AM, Hofheinz RD, Wein A, et al. A phase II trial of second-line irinotecan and capecitabine after failure of first line infusional 5-fluorouracil and folinic acid in metastatic colorectal cancer (MCRC). J Clin Oncol. 2004;22(14S). Abstract 3752.
26. Hofheinz RD, Gnad-Vogt U, Wein A, et al. Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/ folinic acid in advanced colorectal cancer: a phase II study. Anticancer Drugs. 2005;16:39-45.
27. Dickson N, Burris HA, Foulke R, et al. Flat-dose continuous capecitabine with irinotecan (CPT) in 1st line advanced colorectal cancer (ACRC): early results of a phase II trial. Proc Am Soc Clin Oncol. 2003;22. Abstract 1480.
28. Anderson N, Lokich J, Kalman L, et al. Preliminary data on weekly irinotecan (CPT) with continuous capecitabine (X) in metastatic colorectal cancer (MCRC) patients (pts). J Clin Oncol. 2004;22. Abstract 3755.
29. Barrios CH, Viola F, Camillo-Coura L, et al. Phase II study of capecitabine and irinotecan as first-line treatment in metastatic colorectal cancer: first trial of the Brazilian Oncology Consortium (BOC-CRC 001). J Clin Oncol. 2004;22(14S). Abstract 3725.
30. Burris HA, Kalman L, Bertoli L, et al. Continuous flat-dose capecitabine plus weekly irinotecan: an alternative first-line treatment for metastatic colorectal cancer (MCRC). In: American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract 229.
31. Copur MS, Ledakis P, Bolton M, et al. Capecitabine and irinotecan on a two-week on one-week off schedule for previously treated metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2003;22. Abstract 1212.
32. Laudani A, Agostara B, Savio G, et al. Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol. 2006;24(18S):622s. Abstract 13573.
33. Kim TW, Kang WK, Park JO, et al; Korea Cancer Study Group. Phase II study of irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer. Proc Am Soc Clin Oncol. 2003;22. Abstract 1278.
34. Kim TW, Kang WK, Chang HM, et al; Korean Cancer Study Group. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta Oncol. 2005;44:230-235.
35. Park YS, Chun JH, Lee HG, et al. A phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2003;22. Abstract 1321.
36. Ahn J-B, Jung KH, Park YS, et al. Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC). J Clin Oncol. 2005;23: 299s. Abstract 3714.
37. Zidan J, Basher W, Shnaider J, et al. Capecitabine combined with Irinotecan (CapIri) as first line treatment of advanced colorectal carcinoma (ACRC): a phase II study. J Clin Oncol. 2006;24:621s. Abstract 13569.
38. Shin SJ, Ahn JB, Choi HJ, et al. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol. 2008;61:75-81.
39. Park SH, Bang SM, Cho EK, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology. 2004;66:353-357.
40. Michalaki V, Gennatas C, Gennatas S, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. J Clin Oncol. 2007;25:633s. Abstract 14602.
41. Gennatas C, Michalaki V, Gennatas S, et al. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer. Anticancer Res. 2008; 28:1923-1926.
42. Fiorentini G, Dentico P, Cantore M, et al. Capecitabine (XE) plus Irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer (MCRC) in elderly patients: feasibility and safety results from a phase II study. J Clin Oncol. 2005;23:289s. Abstract 3676.
43. Patt YZ, Lee FC, Liebmann JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007;30:350-357.
44. Borner MM, Bernhard J, Dietrich D, et al; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol. 2005;16:282-288.
45. Gold PJ, Godfrey T, Dhami M, et al. Capecitabine and irinotecan as 1st line therapy for patients with metastatic colorectal cancer: phase II study preliminary results. Proc Am Soc Clin Oncol. 2003;22. Abstract 1158.
46. Cassata A, Stani SC, Alù M, et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol. 2001;20. Abstract 573.
47. Munoz Llarena A, Salud Salvia A, García Girón C, et al. Randomized phase III trial, with irinotecan and capecitabine (XELIRI) versus irinotecan, 5FU and folinic acid (Saltz regimen) in first-line treatment on metastatic colorectal cancer patients (CRC). In: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 379.
48. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol. 2008;26:2118-2123.
49. Cassidy J, Twelves C, Van Cutsem E, et al; Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5 fluorouracil/ leucovorin. Ann Oncol. 2002;13:566-755.
50. Camptosar prescribing information. New York, NY: Pfizer, Inc. Available at: http://media.pfizer.com/files/products/uspi-camptosar.pdf. Accessed July 28, 2009.
51. Köhne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308-317.
52. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs. 2004;8(suppl 1): S41-S53.
53. MacLeod A, Branch A, Cassidy J, et al. A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. Eur J Oncol Nurs. 2007;11:247-254